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BENEFITS VERSUS COSTS OF STATIN DRUGS 
Sara Shilcrat 
ABSTRACT 
Statins have been prescribed to the masses as primary and secondary prevention for 
coronary disease caused by hypercholesterolemia after their initial discovery in the late 1980s. 
Their actions in reducing low-density lipoproteins and increasing high-density lipoproteins are 
well documented; however, many negative effects have been reported related to muscle 
pathology and kidney function. The goal of this study is to investigate whether the benefits of 
this class of drugs outweigh the costs. Intense review of the literature was conducted using 
scholarly articles with original research findings that were located via electronic databases such 
as Medline, Science Direct, Proquest Medical Library, and Google Scholar. Research findings on 
the benefits of statins extended beyond their lipid-related effects and included benefits to the 
immune system and inflammatory response, sepsis prevention, and improved endothelial cell 
functions, among others. Negative side effects of statins are many, including damage related to 
skeletal muscle tissue, such as rhabdomyolysis, myofiber necrosis, myotoxicity, myopathy, 
myalgia, reduced muscle resting chloride membrane potential (gCl), vacuolization of the T-
tubule system, sarcolemma detachment, and targeting of the muscle’s mitochondria. Differences 
between type I oxidative myofibers and type IIB glycolytic myofibers are discussed as well as 
the lipophilic and hydrophilic tendencies of the statins in relation to the damage inflicted on 
skeletal muscle tissue. In some rare cases of statin administration, motor neurons displayed 
Amyotrophic Lateral Sclerosis (ALS)-like symptoms that progressed up until muscle 
denervation. Additional negative side effects were seen to the circulatory and excretory systems, 
including altered chemical composition of both the blood plasma and urine, and rare renal failure 
due to rhabdomyolysis. The inquiry as to whether statins affect cardiac muscle as they do 
skeletal muscle is also addressed with the minimal findings that seemed to indicate that cardiac 
muscle is not targeted by statins. 
After taking into account the benefits versus the costs of statins, in addition to the lack of 
a better drug on the market for combating coronary disease, it was suggested that statin 
administration should continue due to its proven cholesterol-related effects. However, statin 
users should be limited to patients with coronary disease triggered by high cholesterol. Patients 
with proven treatment options, such as patients with cancer or autoimmune diseases, were 
cautioned not to take statins for the possible benefits of unproven pleiotropic effects due to the 
likelihood of damage to skeletal muscle and kidney functioning. Monthly blood work and 
urinalysis were also suggested for patients on statins, and patients should be advised to speak to 
their physicians if they feel muscle pain or encountered changes in the ease of manipulating their 
muscles, as these are possible signs of muscle and nerve problems. 
INTRODUCTION 
In 1987, lovastatin, commonly known as Mevacor, Altocor, or Altoprev, was released 
into the public market. This new drug, isolated from the fermentation of the fungus Aspergillus 
terreus, was the beginning of a new class of drugs, marketed by the name of ‘statins,’ that 
focused on lowering cholesterol levels (Statin 2012; Torbert 2003). At the time, knowledge of 
the connection between cholesterol and the formation of plaques, or atheromas, in blood vessels 
was just beginning to develop. Although today it is common knowledge that cholesterol escaping 
from ruptured atherosclerotic plaques is pinpointed as the culprit of many heart attacks, this was 
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yet unknown. Statins evolved from the skepticism that surrounded the lipid hypothesis, a 
controversial idea which associated coronary heart disease with increased levels of low-density 
lipoprotein (LDL) cholesterol and decreased levels of high-density lipoprotein (HDL) cholesterol 
(Statin 2012). Statins, or HMG-CoA reductase inhibitors, effectively stop the metabolic pathway 
ending in the synthesis of cholesterol. This class of drugs inhibits the functioning of an enzyme 
known as HMG-CoA reductase, and as a result, HMG-CoA, or 3-hydroxy-3-methylglutaryl-
Coenzyme A, is not converted into mevalonic acid (Figures 1 and 2). Since this is the first step, 
also known as the rate-limiting step, in the pathway that leads to cholesterol, blocking this 
transformation will stop the entire cholesterol synthesis pathway (Figure 3). With the formation 
of cholesterol at a halt, fewer plaques will form, and subsequently rupture, decreasing the risk of 
heart attacks and other adverse effects of cardiovascular disease. However, in addition to 
blocking the formation of cholesterol which improves the cardiovascular disease prognoses, 
using statins also prevents the formation of other cholesterol derivatives such as isoprenoids and 
sterols including testosterone, estradiol, and cortisol, among others which may result in 
additional repercussions. 
 
 
 
 
 
 
 
 
 
 
 
Today, statins are commonly prescribed as primary and secondary prevention for 
cardiovascular diseases associated with elevated cholesterol levels, or hypercholesterolemia 
(Merx and Weber 2006; Statin 2012). Since the discovery of lovastatin, other statins have 
successively entered the market including simvastatin (1988, as Zocor and Lipex), pravastatin 
(1991, as Prevachol, Selektine, and Lipostat), fluvastatin (1994, as Lescol and Lescol XL), 
atorvastatin (1997, as Lipitor and Torvast), cerivastatin (1998, as Lipobay and Baycol), and 
rosuvastatin (2003, as Crestor) (Torbert 2003) (Figure 4). 
Other prescription drugs on the market, such as Vytorin (simvastatin and ezetimibe), 
Advicor (lovastatin and niacin extended release), Caduet (atorvastatin and amlodipine besylate), 
and Simcor (simvastatin and niacin extended release) combine one of the statins with another 
drug for multiple therapeutic effects (Statin 2012). Also, statins may be prescribed with 
concurrent use of fibrates, immunosuppressants, corticosteroids, antifungals, blood thinners like 
warfarin, and other prescription drugs (Mohaupt et al. 2009; Nicholls et al. 2011). 
Figure 1: HMG-CoA Reductase 
Ribbon Model. Source: HMG-
CoA reductase 2012 
 
Figure 2: 3-Hydroxy-3-methylglutaryl-coenzyme A 
(HMG CoA) Structure. Source: HMG-CoA 2012 
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Figure 3: Cholesterol Synthesis Pathway. Source: Statin 2012 
 
Each of the statins differs in its ability to reduce LDL cholesterol. Ranging from most 
effective to least effective, the statins can be arranged in the following order: cerivastatin > 
rosuvastatin > atorvastatin > simvastatin > lovastatin > pravastatin > fluvastatin (Statin 2012). 
Recommended dosages of the statin drugs differ based on their potency, with less potent statins 
prescribed at higher dosages and vice versa. Statins can also be classified on a continuum of 
being more hydrophilic or more lipophilic, affecting their LDL cholesterol reducing power. 
Differences in a particular statin’s hydrophilicity are thought to cause different physiological 
effects on the body, especially when discussing the effects of statins on skeletal muscle (Pierno 
et al. 2006; Sidaway et al. 2009). 
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Examining the chemical structure of statins shows general similarities that exist in this 
class of drugs (Figure 4). Some key differences do exist, however, between statins that are 
derived from fermented natural substances (mevastatin, lovastatin, pravastatin, and simvastatin
1
) 
and laboratory-created synthetic statins (atorvastatin, cerivastatin, fluvastatin, pitavastatin, and 
rosuvastatin). Generally, the statins consist of two or more ring structures; in synthetic statins, 
one of the rings is a nitrogen-containing heterocyclic ring not found in naturally-derived statins. 
In addition, lacking in the fermentation derivatives, a fluorinated benzene ring is found in the 
synthetic statins as well as a seven-carbon fatty acid chain branching off a ring structure 
terminating in a carboxylic acid. The fatty acid chain is also characterized as a diol, with two 
hydroxyl groups coming off the chain at positions C3 and C5 counting from C1 of the -COOH 
group.. In the naturally occurring statins two fused cyclohexene rings share two carbon atoms 
and have double bonds located a single carbon away from one another. These statins lack the 
fatty acid chain and instead, a cyclic ester with a hydroxyl group attached 2 carbon atoms away 
is present. Additionally, they contain a second ester attached further away on the molecule that is 
followed by a sec-butyl group. Finally, the synthetic statins may contain one or more isopropyl 
groups branching off of the heterocyclic N-containing rings (Table 1). 
The variations in statins’ structures have generated a common assortment of side effects, 
but the individual structure of the statin has been shown to yield differences in the severity of the 
side effects when they are experienced. In 2001, cerivastatin was removed from the market due 
to the severe side effects, specifically rhabdomyolysis, or the breakdown of muscle tissue, which 
led to numerous deaths (Obayashi et al. 2011; Sidaway et al. 2009; Statin 2012). A few more 
common, less severe side effects seen in skeletal muscle after using statins include myotoxicity, 
myopathy, any abnormal condition or disease of muscle tissue, myalgia, or muscle pain, and 
limb weakness. Other adverse side effects seen with statins include increased creatinine kinase 
(CK) activity, increased ryanodine receptor 3 (RYR3) mRNA expression (Mohaupt et al. 2009), 
sarcolemma detachment (Mohaupt et al. 2009), vacuolization of muscle fibers (Mohaupt et al. 
2009; Obayashi et al. 2011), increased myoglobinemia and myoglobinuria (Pierno et al. 2006) , 
reduced sarcolemma resting chloride membrane potential (gCl) (Pierno et al. 2006; Pierno et al. 
2009), muscle fiber necrosis, neuromuscular damage with ALS-like (amyotrophic lateral 
sclerosis) symptoms (Edwards et al. 2007), and kidney damage (Campese and Park 2007). 
Despite these adverse effects, statins have been proven to be very effective at reducing 
LDL cholesterol and boosting HDL cholesterol. Other beneficial actions of statins include 
pleiotropic effects unrelated to lipid mobilization such as sepsis prevention (Hackam et al. 2006 
cited in Merx and Weber 2006), increased KLF2 expression (T cells) (Bu et al. 2010), improved 
endothelium function including increased nitric oxide (NO) production (Liao and Laufs 2005; 
Merx and Weber 2006), and other possible applications for treating autoimmune and 
inflammatory disorders (Bu et al. 2010; Weitz-Schmidt 2003). 
The sale of Lipitor™ (atorvastatin) swept the market, netting Pfizer an unprecedented 
yield in the pharmaceutical industry of more than $12 billion dollars (Statin 2012). Yet whether 
the benefits of statins are really worth the adverse side effects experienced is still under debate. 
Doctors seem bent on continuing to prescribe the statin drugs and tend to taper the dosage as 
needed to mitigate the side effects. But when do the ill effects of statins go so far that it is no 
longer possible to justify their use? To what degree must the body’s chemistry be altered in order 
to stop using statins? 
                                                             
1
Although simvastatin is actually synthetically made from a substance produced by fermenting Aspergillus terreus, 
it closely resembles naturally-derived statins in its structure.   
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Naturally-Derived Statins Synthetic Statins 
Mevastatin 
 
Atorvastatin 
 
 
Lovastatin 
 
Cerivastatin 
 
Pravastatin 
 
Fluvastatin 
 
Simvastatin
1
 
 
 
Pitavastatin 
 
 Rosuvastatin 
 
Figure 4: Structures of the statins. Source: Statin 2012 
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Table 1: Features of the natural and synthetic statins. 
Statins  Poly 
Cyclic 
N-containing 
Heterocyclic 
Ring 
para-
Fluorobenzene 
Ring 
Fused 
Cyclohexene 
Rings 
(Decene 
structure) 
Fatty 
Acid 
with 
Diol 
/COOH 
Cyclic 
Ester 
with 
-OH 
Ester 
with 
sec-
butyl 
Isopropyl 
Groups 
Additional 
Structures 
Natural 
(Fermentation 
derived) 
         
Mevastatin Y N N Y N Y Y N  
Lovastatin Y N N Y N Y Y N  
Pravastatin Y N N Y N Y Y N  
Simvastatin Y N N Y N Y * N  
Synthetic          
Atorvastatin Y Y-pentane Y N Y N N Y Cyclic Amide 
Cerivastatin Y Y-
cyclohexane 
Y N Y N N Y (2) Alkene at C6-
C7 of fatty 
acid chain  
Fluvastatin Y Y-pentane Y N Y N N Y Heterocyclic 
pentane 
attached to a 
benzene ring 
Pitavastatin Y Y-
cyclohexane 
Y N Y N N N Cyclopropane 
and fused 
heterocyclic 
and non-
heterocyclic  
6C rings 
Rosuvastatin Y Y-
cyclohexane 
with 2 N’s 
Y N Y N N Y Methyl- 
Sulfur 
dioxide 
attached to a 
secondary 
amine 
 
 
METHODS 
Review of the literature on statins was done using electronic databases, such as Medline, Science 
Direct, Proquest Medical Library, and Google Scholar to procure articles on or related to statins using 
keywords like ‘statins,’ ‘HMG-CoA reductase inhibitors,’ and the like. 
DISCUSSION 
Benefits of Statins: 
Reduction of LDL cholesterol and increase of HDL cholesterol 
Statins were originally intended for their abilities to reduce LDL cholesterol and increase 
HDL cholesterol. Some studies have shown that modulations of LDLs and HDLs brought about 
by statins may result in regression of coronary disease (Nicholls et al. 2011; Nissen et al. 2004; 
Nissen et al. 2006).In an extended study spanning more than 2 years, 1039 patients with coronary 
disease were treated with one of two statin drugs, atorvastatin (80 mg daily) or rosuvastatin (40 
mg daily), in a randomized clinical trial to determine and compare their individual effects on the 
progression of atherosclerotic plaques (Nicholls et al. 2011). 
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Figure 5: Diagram of an Artery in Cross Section. Source: 
Diagram of an artery in cross section 2008 
 
Percent atheroma volume and normalized total atheroma volume regression 
Before and after the 104-week period, ultrasounds were recorded of a particular artery 
with stenosis. The external elastic membrane of the vessel and the lumen size were measured 
(Figure 5), and the following formulas were used to determine the percent atheroma volume 
(PAV) and the normalized total atheroma volume (TAVnormalized), that allowed for comparison 
between participants who had different atheroma sizes: 
 
PAV = Σ (External Elastic Membranearea – Lumenarea)   × 100 
Σ External Elastic Membranearea  
 
TAVnormalized = Σ (External Elastic Membranearea – Lumenarea) × median no. of no. of images in 
pullback images in cohort. 
 
The changes in PAV and 
TAVnormalized were calculated as 
the PAV or TAVnormalized at week 
104 minus the initial PAV or 
TAVnormalized. Interpreting the 
formulas, an increase in PAV 
corresponds to a decrease in the 
opening size of the lumen, or the 
higher the PAV value, the more 
closed the coronary artery is. The 
TAVnormalized follows the same 
methodology as the PAV, with a 
larger TAVnormalized related to more 
closed arteries in the sample of 
participants. During the 104 week 
period, the HDL and LDL 
cholesterol and triglyceride levels 
of the participants were measured 
at 24, 48, 72, and 104 weeks 
(Nicholls et al. 2011). 
The study showed that the 
two intensive statin regimens lead 
to statistically significant results. 
Both atorvastatin and rosuvastatin 
lowered LDL cholesterol levels 
and increased HDL cholesterol, yet, rosuvastatin was more effective statistically at achieving an 
overall lower LDL to HDL ratio, bringing down LDL cholesterol levels below 70 mg/deciliter in 
many participants, and decreasing the percentage of individuals with LDL cholesterol levels 
above 100 mg/deciliter compared to atorvastatin (Table 2). The PAV and TAVnormalized values 
decreased significantly corresponding to an increase in the lumen size of the participants’ 
blocked arteries due to shrinkage of the plaques. 
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Table 2: LDL and HDL Cholesterol Levels After Intensive Statin Regimens. Source: Nicholls et 
al. 2011 
 Statin (mg/deciliter least-squares mean values ±SD) 
 Atorvastatin Rosuvastatin 
LDL cholesterol levels                       
(p < 0.001) 
  
  at baseline 119.9 ±28.9 120.0 ±27.3 
  at 104 weeks 70.2 ±1.0 62.6 ±1.0 
HDL cholesterol levels              
(p = 0.01) 
  
  at baseline 44.7 ±10.7 45.3 ±11.8 
  at 104 weeks 48.6 ±0.5 50.4 ±0.5 
 
 
Although the PAV showed a slightly greater reduction with rosuvastatin than 
atorvastatin, it was not statistically significant, yielding similar effectiveness in both statins. With 
respect to the TAVnormalized, rosuvastatin did significantly reduce the TAVnormalized value more 
than atorvastatin. Rosuvastatin was also more effective in reducing the PAV in women, 
participants with higher initial HDL cholesterol levels, and in participants with higher initial 
LDL levels. Two interesting abnormalities found in the participants’ lab work were increased 
levels of a liver enzyme, alanine aminotransferase, in the atorvastatin group and more proteinuria 
in the rosuvastatin group (Nicholls et al. 2011). Alanine aminotransferase, or alanine 
transaminase, is an enzyme found in both hepatocytes and myocytes that reversibly converts 
glutamate to α-ketoglutarate, leading to the formation of pyruvate. Gluconeogenesis converts 
pyruvate to high-energy glucose; the glucose can then be utilized by the cell. Alanine 
aminotransferase is used in enzymatic assays and indicates signs of liver damage and/or 
myopathy (Nelson and Cox 2005; Alanine Transaminase 2012). 
This experiment is a clear indicator of the efficiency of statins at yielding mean LDL 
cholesterol levels below the recommended 70 mg/deciliter for secondary prevention of coronary 
disease. HDL cholesterol levels also came close to the recommended 50 mg/deciliter, leading the 
researchers to believe that if given enough time, the statin regimen would meet the desired levels 
for HDL cholesterol and LDL cholesterol and facilitate the regression, or at least deter the 
progression, of coronary disease (Nicholls et al. 2011). 
Other research has found similar results with pravastatin and atorvastatin (Nissen et al. 
2004), and rosuvastatin (Nissen et al. 2006). Still, a major consideration is that although the PAV 
reflects reduction in the size of a particular atherosclerotic plaque, it does not necessarily 
translate into preventing an impending cardiovascular episode. Second, TAVnormalized regression 
has not been linked to any clinical significance.  Finally, although disease advanced in one third 
of the participants even with the heavy statin regimen, results indicate the beneficial aspects of 
statins with regard to cholesterol and plaque regression and demonstrate the general safety of 
statins even at high doses (Nicholls et al. 2011).  
Pleiotropic effects 
Statins have been found to aid in a variety of other functions (Liao and Laufs 2005). 
Immune responses and inflammation: 
Effects on T lymphocytes and KLF-2 gene expression 
T cells are important actors in the inflammatory responses of the body. Statins were 
proven to upregulate the expression of the Kruppel-like factor 2 (KLF-2) gene in activated, or 
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effector, CD4+ helper T cells and CD8+ cytotoxic T cells, and prevent the downregulation of 
KLF-2 that normally occurs in recently activated T cells (Bu et al. 2010). The KLF-2 gene is 
thought to inhibit T cell proliferation that occurs with inflammatory responses and keeps T cells 
in a resting state as KLF2 mRNA is expressed in naïve and memory T cells (Buckley et al. 2001 
and Kuo et al. 1997 cited in Bu et al. 2010). 
Effects on immune cells and LFA-1 binding 
site 
A second pleiotropic effect seen with 
lovastatin in particular is its ability to bind to 
a novel site on LFA-1, lymphocyte function-
related antigen 1, an integrin molecule found 
on T lymphocytes and macrophages (Weitz-
Schmidt 2003). Acting as an allosteric 
inhibitor, lovastatin changes the conformation 
of the LFA-1 and decreases its affinity for its 
substrate intercellular adhesion molecule-1 
(ICAM).   ICAM, is a molecule found on 
endothelial cells that binds to integrins (the 
adhesion molecules found on immune cells). 
During diapedesis, macrophages and T 
lymphocytes will roll and attach to selectin 
molecules expressed on the endothelial 
surface (Tortora and Derrickson 2012; 
Watanabe and Fan 1998). Subsequently, the 
immune cells will strengthen their attachment 
to the endothelium using β2 integrins on their 
surface, such as LFA-1 and bind to members 
of the immunoglobulin family, like ICAM-1, 
located on the endothelium. Binding at these 
two sites will lead the immune cell to squeeze 
between adjacent endothelial cells and reach 
the site of inflammation. ICAM-1 has been 
found to be expressed by endothelium where 
cholesterol-induced plaques are beginning to 
form. Atherosclerotic plaques are thought to 
be induced by the sticking of T cells and other 
immune cells to the endothelium lining blood 
vessels (Figure 6) (Watanabe and Fan 1998). 
If statins change the binding site shape of 
LFA-1 receptors on immune cells, there will 
be less attachment of the immune cells to the 
linings of blood vessels, possibly leading to 
less atherogenesis (Weitz-Schmidt 2003). 
This may explain the plaque regression seen 
in clinical trials, however, in previous studies 
lovastatin was not the statin being studied 
Figure 6: A postulated hypothesis for the 
pathogenesis of atherosclerosis. 
(A) A normal arterial wall. (B, C) Monocytes and T 
lymphocytes adhere to the endothelial cell surface and 
subsequently enter subendothelial space. Monocytes 
are transformed into macrophages and some become 
foam cells after uptake of lipids. (D) Most 
macrophages become foam cells and smooth muscles 
cells in the media start to migrate into the media and 
proliferate. These cells constitute the typical fatty 
streak lesion. EC: endothelial cell, SMC: smooth 
muscle cell, IEL: internal elastic lamina. Source: 
Watanabe and Fan 1998 
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(Nicholls et al. 2011; Nissen et al. 2004; Nissen et al. 2006). It is therefore possible that other 
statins may change additional receptors besides LFA-1on immune cells that are involved in 
attaching them to the endothelium. Alternatively, it is also possible to conjecture that statins may 
modulate adhesion molecules on the endothelial surface or that statins other than lovastatin may 
have another entirely different method for diminishing the size of plaques. 
Statins are also involved in increasing the synthesis of nitric oxide gas by stimulation and 
upregulation of endothelial nitric oxide synthase (Laufs et al. 1998 and Kureishi et al. 2000 cited 
in Liao and Laufs 2005). 
Sepsis prevention 
 Some research has found evidence of fewer cases of sepsis, including moderate to 
severe, and even fatal, sepsis cases when patients were taking statins compared to matched 
controls (Hackam et al. 2006). 
Costs of Statins: 
Statins have been proven to cause a wide range of negative side effects many of which 
target muscles, but damage can also occur to nerves innervating skeletal muscles and the kidneys 
as well. 
Damage to skeletal muscle 
There are two possible mechanisms for how damage occurs. These will now be 
discussed. 
Targeting the mitochondria 
It is necessary to understand how statins lead to skeletal muscle degradation in order to 
fully grasp the extent of their effects on the body. A study of cerivastatin in male rats implicates 
its targeting of mitochondria as a plausible cause of muscle toxicity (Obayashi et al. 2011). The 
researchers studied effects to the soleus muscle, a muscle rich in type I fibers, and the extensor 
digitorum longus and the tibialis anterior, muscles rich in type II fibers, throughout the course of 
cerivastatin treatment. While no particular skeletal muscle is purely made up of one type of 
muscle fiber (i.e. type I, IIA or IIB) (Swenson 2006), a particular muscle may contain a larger 
percentage of one of the three types of fibers; researchers tend to choose these muscles to study 
in order to determine trends in muscle fiber types after statin administration While light 
microscopy did not show any visible signs of damage to any of the three muscles on day 6, 
electron microscopy of the soleus muscle revealed mitochondria that were swollen, electron 
dense, deteriorated, and contained inclusion bodies  Other abnormalities included autophagic 
vacuoles, some of which were consuming membrane-bound organelles, activated lysosomes, 
myeloid structures, and disorderly myofibrils. By day 8, the soleus muscle of the cerivastatin-
treated rats showed enlarged mitochondria in addition to vast differences in the diameter of the 
myofibers and some very darkly staining myofibers. 
Overall, the mitochondria in this study showed changes in shape, becoming rounded as 
opposed to oval, and were sought out and destroyed by lysosomes. Only after the destruction of 
the mitochondria were myofibrils jumbled and autophagic vacuoles active. These findings led to 
the logical premise that mitochondria are targeted by cerivastatin (Obayashi et al. 2011). While 
this and other studies zero in on the damaging effects of statins to mitochondria as the primary 
targets, this idea has been challenged (Waclawik et al. 1993, Schaefer et al. 2004, and Westwood 
et al. 2008 cited in Obayashi et al. 2011). 
Statins’ effects on mitochondria in relation to susceptibility of muscle fiber type to damage 
Examination of the mitochondria activity in Hanai et al.’s experiment (2007), discussed 
below, reinforces a likely conclusion as to why type IIB fibers are more susceptible to statin-
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associated muscle damage and why type I fibers are resistant to such damage. Since type IIB 
fibers lack two protective factors found in type I fibers, specifically more numerous 
mitochondria and greater expression of a gene that halts tissue atrophy known as PGC-1α, they 
are likely more vulnerable to damage by statins. Alternatively, if statins target mitochondria in 
particular, type IIB fibers are at a loss, already having fewer mitochondria with the compounded 
problem of the statins depleting the few mitochondria that these fibers have left. 
Nonetheless, the argument that type IIB fibers are more vulnerable to statins was not seen 
in Obayashi et al.’s study of cerivastatin in rats (2011). Damage in this experiment was delivered 
solely to the soleus muscle, a predominantly type I oxidative, slow twitch muscle. Both the 
tibialis anterior and the extensor digitorum longus muscles, fast twitch, glycolytic type IIB-
predominant muscles, did not show the damage seen to the soleus’ mitochondria. This 
contradiction may be reconciled by stressing which statin was used in Obayashi et al.’s study 
compared to that by Hanai et al. in 2007, namely cerivastatin versus lovastatin. It is possible that 
these two statins have different methods of inducing skeletal damage. Extrapolating a step 
further, it seems logical that cerivastatin’s potency, leading ultimately to its removal from the 
public market, may be linked to changes in the mitochondria seen in type I fibers. It may be that 
rhabdomyolysis of type I myofibers specifically may be more serious overall, both from a 
physiological and function-related point of view. Anatomically, these muscle cells contain large 
amounts of myoglobin, which will be released into the blood plasma, to be dealt with by the 
kidneys if the muscle breaks down. Functionally, type I fibers resist fatigue from long term 
exercise, maintain sustained contracture for long time periods, act when only weak muscle 
contracture is needed, and finally, may compromise up to half of the fibers in a particular muscle 
(Tortora and Derrickson 2012). Conversely, lovastatin and other statins may act in a different 
manner that causes muscle damage primarily to type IIB fibers (Hanai et al. 2007; Schaefer et al. 
2004; Smith et al. 1991 cited in Sidaway et al. 2009; Westwood et al. 2005; Pierno et al. 2006). 
Alternatively, mitochondria contain the necessary components of oxidative 
phosphorylation, one of which is CoQ10. CoQ10 is a protein produced by the prenylation pathway 
that stems from HMG-CoA being converted to mevalonic acid (Figure 3). Since statins inhibit 
HMG-CoA reductase, less CoQ10 is made than may be needed by the mitochondria. When there 
is abundant PGC-1α expression, it is possible that the more massive mitochondria that are 
produced by expression of this gene will intrinsically have more CoQ10 and will not need to rely 
on the synthesis of new CoQ10. from HMG-CoA reductase activity, inhibitable by statins. As of 
yet, this idea is still under assessment (Hanai et al. 2007) Again, if CoQ10 is the problem, the 
same logic applies as to why type IIB fibers are more susceptible to statins compared to type I, 
namely the limited amounts of mitochondria present. If the amount of CoQ10 is similarly 
lessened in all mitochondria, still the overall quantity of CoQ10 in type I muscles will likely 
exceed that found in type IIB muscles just by a greater number of mitochondria. The increased 
mitochondria, and as a result CoQ10, in the type I fibers will then not be as severely affected by 
the statin-induced shortage of the CoQ10, a mainstay of the electron transport system. 
Potency of cerivastatin 
Cerivastatin was determined as the most potent statin since a dose less than 20 mg/kg, of 
cerivastatin, which does not cause myopathy with other statins, generated myopathy (Sidaway et 
al. 2009). While cerivastatin does cause severe rhabdomyolysis, it must be remembered that this 
is a rare side effect that was not found in preliminary testing but seen after release into the mass 
market. Since it is truly an unusual side effect of statins and linked mainly to the retracted 
cerivastatin, it would be wont to discontinue use of this entire class of drugs due to fear of this 
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particular adverse reaction. Therefore, it would not be reasonable to stop prescribing statins to 
the masses, yet this side effect should be monitored closely in the rare chance that there are signs 
of myopathy in a particular patient. 
Atrogin-1 expression inducing muscle atrophy 
Another study discusses a second mechanism for statins’ effects on skeletal muscle. In 
this mechanism, statins are thought to switch on the expression of a gene involved in a pathway 
leading to atrophy in body tissues (Hanai et al. 2007). The gene, atrogin-1/MAFbx, is part of the 
ubiquitin proteasome pathway (UPP), a pathway involved in protein breakdown in the body, and 
codes for an enzyme called ubiquitin-protein ligase that is specific to muscle tissue. Elevated 
atrogin-1 mRNA levels were found in skeletal muscle biopsies
2
 of patients with statin-associated 
myopathy and in patients with myopathy that were not taking statins compared to healthy 
controls. Lovastatin was introduced to C2C12 myotubes (skeletal muscle cell precursors) and 
zebrafish embryos to determine whether there would be a similar abundance of atrogin-1 
expression in these organisms after treatment. In the myotubes, increasing amounts of lovastatin 
resulted in commensurate increases in the amount of atrogin-1 mRNA, its corresponding protein, 
and muscle proteolysis. Larger amounts of lovastatin lead to markedly shrunken myotubes. The 
cells progressively deteriorated displaying evidence of vacuoles and extreme distortion ending in 
the loss of the myotubes after 5 days (concentrations of lovastatin included 0.0, 0.25, 1.0, 2.5, 
5.0, and 10.0 µM). Vacuolization of the myotubes may reflect the vacuolization that is seen in 
skeletal muscle tissues in the T-tubule system reported by Mohaupt et al. (2009). The researchers 
also proved that the atrogin-1 gene was needed to cause lovastatin-induced morphology changes 
in the myotubes; myotubes bred lacking the atrogin-1 gene and then dosed with a particular 
concentration of lovastatin (either 0.0, 0.01, 0.05, 0.25, 1.0, or 2.5 µM) did not show changes to 
the diameter and morphology of the myotubes unlike matched atrogin-1-containing myotubes at 
the parallel dose of lovastatin (Hanai et al. 2007). What is interesting to note is a slight dip in 
myotube diameter when atrogin-1 null myotubes were dosed with 2.5 µM of lovastatin. Whether 
this would decrease enough to become significant with 5.0 µM or 10 µM concentration will 
remain unknown as the researchers did not continue to dose the myotubes with these increasing 
concentration levels.  It is also possible that ≥5.0 µM lovastatin concentration greatly exceeds the 
amount of lovastatin that would be given to a patient in a clinical setting per kilogram. Yet this 
rationale is hard to justify as wild-type for atrogin-1myotubes were initially dosed at these 
concentrations to determine the effects to the myotubes. 
Depending on the dosage, lovastatin triggered specific morphological changes in the 
skeletal muscle of zebrafish embryos which were dosed 20 hours post fertilization (Hanai et al. 
2007). Changes to zebrafish skeletal muscle morphology were determined by exogenously-
prepared antibodies that, upon reacting with skeletal muscle tissue, would latch on to myosin 
found in the thick filaments. These morphological changes in the muscle were classified based 
on their severity. Class 1 changes to muscle consistent with 0.025-0.05 µM lovastatin treatment 
included bowing, gap formation, and disruption of the muscle fibers. Increasing the lovastatin 
dosage, class 2 morphological changes (0.05-0.5 µM) comprised thin/irregular or diffuse 
appearance of the myosin strands. Finally, irregular muscle segment boundaries were categorized 
under class 3 changes due to lovastatin treatment (1.0-5.0 µM). 
Confirmation of statins’ inhibition of HMG-CoA reductase in zebrafish embryos 
The effects of lovastatin were confirmed to be the result of HMG-CoA reductase 
inhibition. After knocking out the HMG-CoA reductase gene and eradicating any corresponding, 
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 Biopsies were taken from the quadriceps. 
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loose mRNA in the cell with antisense technology, the skeletal muscle showed similar 
morphological characteristics to the class 1 ‘disrupted’ muscle fibers of the zebrafish treated with 
lovastatin (wild-type for  HMG-CoA reductase and atrogin-1 genes (Hanai et al. 2007). 
Muscle myopathy 
The relationship between histological damage of skeletal muscles and painful muscles 
thought to be caused by statins has been studied (Mohaupt et al. 2009). The vastus lateralis of 83 
participants were biopsied. Participants were divided into 5 experimental groups (Table 3). 
Participants in group 4 (n=29) were presently taking atorvastatin (17%), simvastatin (41%), 
fluvastatin (7%), pravastatin (31%), or rosuvastatin (3%), and they had previously been 
prescribed 4 out of the 5 statins currently being used
3
. Group 5 participants (n=19) currently on 
statins without symptoms of myopathy reported prescriptions for simvastatin (74%) and 
pravastatin (21%), while in the past, one of the participants had been on simvastatin. As for the 
participants in group 3 whom had ceased their statin regimens (n=15), the statins previously 
prescribed included atorvastatin (40%), simvastatin (53%), fluvastatin (7%), pravastatin (53%), 
and cerivastatin (7%). A careful record of other drugs being used alongside statins were 
documented including fibrates, immunosuppressants, corticosteroids, blood thinners, macrolid 
antibiotics, antifungals, and HIV-protease inhibitors. The biopsies were studied for microscopic 
anatomical variances in the skeletal muscle’s structure. For the skeletal muscle damage to be 
considered significant, the researchers mandated that a minimum of 2% of the myofibers from 
the biopsy needed to show clear evidence of destruction (Mohaupt et al. 2009). 
 
 
Table 3: Groups 1-5 for Experiment Relating Statin-Induced Myopathy to Muscle Injury. 
Source: Mohaupt et al. 2009 
Group Condition Currently On 
Statin Regimen 
Y/N 
Pre-existing 
Statin-Induced 
Myopathy 
Y/N 
No. of 
Participants 
Gender 
1 Healthy N N 10 Male 
2 Hypercholesterolemia 
(Unrelated to 
muscles) 
N N 10 (Age 
matching to 
Groups 3 & 
4 ) 
7 Males 
3 Females 
3 Clinically Diagnosed 
Myopathy 
N (At least 3 
weeks off 
treatment 
regimen) 
Y 15 8 Males 
7 Females 
4 Clinically Diagnosed 
Myopathy 
Y Y 29 22 Males 
7 Females 
5 Hypercholesterolemia Y N (reported no 
muscle 
problems) 
19 12 Males 
7 Females 
 
 
                                                             
3
 Rosuvastatin was not prescribed previously (Mohaupt et. al. 2009). 
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Patient-reported symptoms of myopathy in groups 3, 4, and 5 
About two thirds (67%) of those who discontinued statin use (group 3) and 
approximately half (48%) of the current statin users (group 4) were presently suffering from 
myalgia, or muscle pain (Table 4). Another symptom of myopathy expressed by one fifth of past 
statin users and 38% of current statin users was muscle weakness in the torso and upper arms. A 
lesser noted symptom of myopathy found was muscle cramping (13% in group 3 participants and 
7% in group 4). Finally, 3 out of 15 (20%) participants in group 3 who discontinued statin use 
mentioned experiencing myalgia, muscle weakness, and/or cramping lasting more than a month 
after discontinuing statin use (Mohaupt et al. 2009). 
 
 
Table 4: Results of Experiment Relating Statin-Induced Myopathy to Muscle Injury for Groups 
3-5. Source: Mohaupt et al. 2009 
Group 3 4 5 
Myopathy Symptoms    
Myalgia No. (%) 10 (67) 14 (48) N/A 
Weakness No. (%) 3 (20) 11 (38) N/A 
Cramping No. (%) 2 (13) 2 (7) N/A 
Myopathy Symptoms Lasting More than 1 
month after Discontinuing Usage of Statins 
No. (%) 
3 (20) N/A N/A 
No. of Weeks Since Discontinuing Statin 
Usage, Median (Range) 
12 (3-300) N/A N/A 
No. of Participants with Significant Muscle 
Damage 
9 16 1 
No. of Damaged Myofibers in Participant(s) 
with Significant Muscle Damage 
No. (%) {Percentage Range of Damaged 
Myofibers Having Lesions} 
9 (60) {2.8-100%} 9 (60) {3.3-43%} 1 (5) 
Percentage of Fibers Injured Median value 9.0% 9.5% N/A 
 
 
Experimental results showing specific skeletal muscle damage linked to myopathy 
With regard to damaged muscle fibers, participants in group 3 and group 4 showed 
evidence of significant muscle fiber damage in the form of lesions to their vastus lateralis 
muscles compared to the control group. Furthermore, of the 25 participants with skeletal muscle 
injury, 21 (84%) were actively using statins
4
. When viewing the muscles using light and electron 
microscopy, there was evidence of intact sarcolemmas detaching from the contracting part of the 
muscle. Other findings specific to statin users with myopathy (and not found in matched 
controls) included ghost cells (deteriorated cells with hollow T-tubules), inconsistency in muscle 
cells’ sizes, and vacuolization of the T-tubules. 
This experiment reveals that many patients presenting with statin-induced myopathy did 
have structural muscle damage. This is an alarming result as now myopathy may need to be 
                                                             
4
 This article (Mohaupt et al. 2009) is problematic as only 16/25 participants with skeletal muscle injury are current 
statin users (group 4). 
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considered as a more serious “red flag”, indicating the start of muscle damage. The authors also 
pinpointed the appearance of myofibers with damage being limited to the T-tubules and the 
detachment of the sarcolemma. They hypothesized that the vacuoles formed in the T-tubule 
passageways may lend themselves to making the muscle susceptible to greater damage. Vacuoles 
in the T-tubule system may prevent the even transmission of an action potential to all myofibers, 
impeding proper muscle contraction. Further investigation is needed to clearly define how 
vacuoles in the T-tubules affect muscle fiber function. The other major finding, detachment of 
the sarcolemma, may also be problematic as it may prevent the proper depolarization of the 
membrane, leading to inconsistencies in muscle contraction. Further, the researchers suggested 
that the creatine phosphokinase did not leak into the blood stream, preventing a rise in blood 
creatine phosphokinase levels, due to the intact nature of the sarcolemma. 
Expression of calcium homeostasis genes in myopathy patients’ vastus lateralis muscles 
In addition, the expression of mRNA for 8 different genes coding for proteins found in 
the T-tubules and adjoining sarcoplasmic reticulum was studied (Mohaupt et al. 2009). All of the 
genes chosen by the researchers correspond to proteins that are involved in intracellular calcium 
ion homeostasis. Calcium’s importance lies in the fact that it is essential for muscle contraction 
(Tortora and Derrickson 2012). Calcium release from the sarcoplasmic reticulum is carefully 
regulated by proteins in muscle cells to prevent unwanted contractions; the researchers chose to 
study the expression of these genes to determine fluctuations in their concentrations related to 
myopathy in patients (Mohaupt et al. 2009). 
Of the 8 genes related to calcium homeostasis that were studied, only one of the genes, 
the ryanodine receptor-3 (RYR3) gene, was expressed in greater quantities in participants with 
structural muscle injury (n=25). Ryanodine receptor-3 is found in variable amounts in adult 
skeletal muscle tissue along with ryanodine receptor-1 (RYR1). The high amounts of ryanodine 
receptor-3 mRNA were thought to be linked to problems with calcium homeostasis; however, the 
experiment could not prove if the increased amounts of the mRNA were caused by statin-
induced muscle damage or by increased expression of the gene before using statins. mRNA for a 
different gene coding for sarcoplasmic reticulum transporting Ca
2+
 ATPase 3 was also found in 
greater quantities in participants with muscle injury, however, it was not found statistically 
significant, which the authors attribute to the diversity in the expression of this gene (Mohaupt et 
al. 2009). 
This study is inherently problematic. Limitations of this study include 
a) the small size of the experimental groups,  
b) the lack of data indicating an average amount (with a range) of myofibers biopsied from 
participants in a particular group and, 
c) neglecting to mention the average size of the myofibers, 
d) ambiguousness and miscalculations mentioned previously,  
e) the presumably small amount of myofibers biopsied, 
f) determination of the significance of 2% of myofibers being damaged in the biopsy 
sample, which was thought to be  low for the amount of myofibers sampled
5
, 
g) the variety of statins that the participants were taking, and lastly,   
h) failing to follow up with participants. 
                                                             
5 Participants did not report feeling any pain from this muscle (Mohaupt et al. 2009).   
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The significance level of 2% of the myofibers displaying damage is most problematic in 
this study. One myofiber may range from 100 microns to a few centimeters in length once it 
matures (Skeletal Muscle Fiber Structure 2005; Tortora and Derrickson 2012); in this 
experiment, a 3 mm x 6 mm biopsy yielded only 15-20 cells, totaling about 2.5-5 cells/mm. This 
translates to less than a third of one myofiber from those biopsied had to show structural damage 
to be considered significant. Finally, the researchers discussed that 
i) no clear definition was established for what constituted statin-induced myopathy (i.e. 
certain symptoms etc.) before beginning the study, 
a very serious oversight. From this study, numerical data should not be used to support any 
conclusions due to the ambiguities and inconsistencies in the way in which the article was 
written. Nonetheless, the electron micrographs are still valid, and anatomical changes to the 
muscle fibers can be believed as these changes were similar to those seen in other experiments 
(Obayashi and colleagues in 2011 and Hanai and colleagues in 2007). 
Muscle myopathy in relation to statin accumulation in muscle fibers and/or systemic tissues 
Studies of statins also fixate on whether the amassing of sta tins has a toxic effect on 
muscle and systemic tissues. A study performed with rodents with statin-induced myopathy 
focused on determining how statins buildup in muscle and body tissues over time in order to 
explain unusual cases of delayed onset of myopathy (Sidaway et al. 2009). Further, a comparison 
of the accumulation of statins in skeletal muscle with predominantly type I versus type IIB fibers 
was assessed. In previous studies, slow-twitch, oxidative, type I skeletal muscle fibers were 
found resistant to necrosis caused by statins, while fast-twitch, glycolytic, type IIB skeletal 
muscle fibers were more susceptible to cell death due to statin usage (Smith et al. 1991; Schaefer 
et al. 2004; Westwood et al. 2005 cited by Sidaway et al. 2009). 
Experimental methods for testing statin accumulation 
Statin-induced myopathy was induced in female rats by treatment with one of the 
following three statins: cerivastatin, simvastatin, or rosuvastatin. A fourth group of rats was 
given a smaller dose of rosuvastatin which was not anticipated to cause myopathy. After 
anywhere from 5-16 days, blood was drawn for creatinine kinase activity testing. Creatinine is a 
byproduct of metabolized creatine that is found in muscles and is filtered by the kidneys. 
Creatinine is an indicator of renal functioning, specifically the glomerular filtration rate 
(Creatinine 2012). Blood samples and skeletal muscle samples (from the soleus muscles and 
right gastrocnemius) were collected and preserved throughout the 16 day period at scheduled 
intervals. The muscle samples were inspected under light microscopy for signs of myopathy 
based on necrosis found in 2 or more muscles or if the plasma creatinine kinase levels exceeded 
1000 IU1
-1
. 
Additionally, the muscle samples were tested for statins and cholesterol metabolites using 
the HMG-CoA reductase enzyme inhibition assay. On days 1 and 5, cerivastatin and simvastatin 
were distributed in doses large enough to cause myopathy, but no myopathy was determined at 
this time. Further monitoring of the rats during days 5-8 still showed no evidence of myopathy in 
any of the three statins. At days 10-16, the first signs of myopathy were evident in half of the rats 
in each of the three experimental statin groups (Sidaway et al. 2009). 
Location of statin exposure 
While the soleus and gastrocnemius muscles during the 16 day experiment showed very 
similar statin exposure for the three experimental groups, comparison of the muscles to the blood 
plasma revealed an unequal distribution of active statin metabolites. Accumulation of statin 
metabolites favored the skeletal muscles over the blood plasma. Studying the ratio of the active 
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statin drug in the gastrocnemius muscle compared to the amount of active drug found in the 
plasma, the three statins differed with the largest ratio calculated for simvastatin
6
 > cerivastatin > 
rosuvastatin. The results denoted a greater amount of simvastatin concentrated in the 
gastrocnemius muscle relative to the blood plasma compared to the other statin drugs. Similar to 
the muscle/blood plasma ratio of statin exposure, a ratio of statin buildup in the liver was 
compared to the blood plasma as well. For cerivastatin, the ratio was very high (96.85) compared 
to the ratio seen with simvastatin (4.02) (Sidaway et al. 2009). 
Conclusions disproving statin accumulation correlated to myopathy in both systemic and 
skeletal muscle tissues 
Important conclusions were deduced from this study. Specifically, the method by which 
statins generated myopathy was not related to the previously-held notion of statin accumulation, 
either in the skeletal muscles or the systemic tissues. Accumulation of statins was ruled out as 
the cause of statin-induced myopathy due to stable levels of statin exposure in the body tissues 
from the initial dosage to the dosage on day 5. The trend continued in days 5-12 with no 
significant accumulation of statins in the systemic tissues during this time, yet signs of myopathy 
were starting to develop. This means that before and during myopathy no differences were seen 
in statin exposure levels. It is therefore a logical conclusion to attribute delayed onset of statin-
induced myopathy to some other mechanism besides prolonged statin exposure in systemic 
tissues (Sidaway et al. 2009). 
Conclusions about whether statin accumulation differs in muscle fiber type 
A second important finding was related to the type of muscle fiber affected by the statin 
treatment. Past studies have isolated the fast-twitch, glycolytic, type IIB skeletal muscle fibers as 
the most susceptible to necrosis from statin-associated myopathy; in this research study, no 
difference was found in the amount of statin accumulation between the two types of muscle 
fibers for any of the three statin therapies. The similarity in statin buildup in the muscles lead to 
the conclusion that differences in the susceptibility of muscle fibers to necrosis from statins is 
based on the biochemistry and physiology of the fibers and not their individual statin-
accumulating tendencies (Sidaway et al. 2009). 
Lipophilicity vs. hydrophilicity in statins and its effect on statin accumulation in muscle fibers 
The researchers also brought up the important concept of lipophilic versus hydrophilic 
tendencies of the statins. While no significant difference was found between muscle fiber types 
and statin buildup, there was some accumulation of statins in the muscle cells. When creating a 
ratio between the statins’ exposure in muscle compared to the blood plasma, the ratio was tipped 
more in favor of the muscle cells for cerivastatin and simvastatin. The penetrance of these two 
statins reflects their characteristic propensity towards being slightly more lipophilic, and the 
researchers conjecture that the method by which these two statins cross the phospholipid bilayer 
of the myofiber and enter the cells is based on diffusion and not transporters
7
 (Sidaway et al. 
2009). 
Lipophilic statins and increased myopathy 
While lipophilic and hydrophilic statins have led to myopathy in skeletal muscle, another 
study verified the hypothesis that lipophilic statins in particular increase the risk of myopathy 
due to their ability to cross the phospholipid bilayer of the cells’ plasma membrane. A study was 
                                                             
6
 The ratio for simvastatin was the same for both the 80 mg and 20 mg simvastatin experimental groups (Sidaway et 
al. 2009). 
7
 Conversely, when the researchers studied the liver, transporters were thought to bring statins into the hepatocytes 
(Sidaway et al. 2009). 
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conducted on rats that tested two different statins, fluvastatin and atorvastatin. First, the statins 
were examined for their typical lipid-related results
8
. Then the rodents were euthanized, and the 
tibialis anterior, soleus muscle, heart, liver, and kidneys were extracted to determine their weight. 
In the fluvastatin rats taking 20 mg/kg/day, the tibialis anterior showed a significant reduction in 
weight, however, the soleus muscle did not show this reduction. Furthermore, the heart and 
kidney of the high dose fluvastatin rats were significantly heavier than the control rodents. This 
finding was dose-dependent as the rats on 5 mg/kg/day dosage of fluvastatin did not show 
differences in the sizes of their muscles or organs. Rats on atorvastatin did not show significant 
differences in organ sizes or muscle except for an increase in muscle size of the tibialis anterior 
muscle (Pierno et al. 2006). 
Alteration to resting chloride membrane potential (gCl). gCl reduction 
Pierno et al. in 2006 proved that vast changes occur to the resting membrane chloride 
conductance (gCl) and the overall ability for sarcolemma excitement when using statins. Resting 
chloride membrane potential/conductance is an important indicator of sarcolemma functioning in 
muscle tissue. The gCl stabilizes the membrane after an action potential and assists in 
repolarization of the membrane for future action potentials (Bryant and Conte Camerino 1991 
and Jentsch et al. 2002 cited in Pierno et al. 2006; Aromatans and Rychkov 2006 cited in Pierno 
et al. 2009). Rats on the 20 mg of fluvastatin showed a significant decrease in myofiber diameter 
of the extensor digitorum longus muscle and gCl (29% reduction), similar to atrophy seen in the 
tibialis anterior mentioned previously. Although rats on atorvastatin and 5 mg fluvastatin had 
larger myofiber diameters than the control rats, the gCl showed the same trend as in the high 
dose fluvastatin rats with atorvastatin rats having a 24% reduction in gCl and 5 mg fluvastatin 
rats having a 20% reduction in gCl. 
Changes in four key factors related to muscle excitability due to reduced gCl 
With the reduced gCl, the muscle fibers after exposure to statins tended to display more 
excitable behavior that was determined by measuring the following factors:  
a) the smallest current needed to procure an action potential, 
b) the amount of elapsed time between turning on the current and the first depolarizing spike 
that indicates the start of an action potential,  
c) the maximum number of action potentials that could be elicited by a myofiber when 
stimulated by a current of a particular value in a 100 millisecond time period, and  
d) just how depolarized a myofiber became after an action potential.   
The following table reflects the changes to these four factors in each of the experimental groups 
(Table 5). 
 
 
 
 
 
 
 
 
                                                             
8
 An increase in HDL cholesterol was found in the rats on atorvastatin only, but for these rats, the total amount of 
cholesterol remained the same. Fluvastatin, with both the 5 and 20 mg/kg/day dose, showed modest reduction of 
total cholesterol of the rats, but no significant increase in HDL cholesterol in particular (Pierno et al. 2009). 
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Table 5: Effects of atorvastatin and fluvastatin on membrane excitability of extensor digitorum 
longus muscle fibers in rats. Source: Pierno et al. 2006 
Statin Treatment 
Muscle Fiber Excitability Changes 
A B C D 
Fluvastatin, 20 mg Decrease Increase Increase Slight increase 
Fluvastatin, 5 mg No change Increase Increase Slight increase 
Atorvastatin, 10 
mg 
No change Increase Increase No change 
A – the smallest current needed to procure an action potential; B – the amount of elapsed time 
between turning on the current and the first depolarizing spike that indicates the start of an action 
potential; C – the maximum number of action potentials that could be elicited by a myofiber 
when stimulated by a current of a particular value in a 100 millisecond time period; D – just how 
depolarized a myofiber became after an action potential. All information is based on comparison 
to control. 
Changes in voltage threshold for mechanical activation in muscle cells due to statins 
Another factor examined was the voltage threshold for mechanical activation in 
myofibers extracted from the extensor digitorum longus muscles of the 4 rodent experimental 
groups (Pierno et al. 2006). The voltage threshold for mechanical activation relates to the amount 
of time needed at a specific current value to cause depolarization of the myofiber, ranging 
anywhere from 5-500 milliseconds. After subjecting the myofibers of control and statin-treated 
rats with a particular current for a set amount of time, contraction occurred more readily in the 
statin-treated rats than the controls. What was more interesting is the fact that the statin-treated 
rats had more negative resting potentials to begin with compared to the controls, yet they could 
reach the threshold for depolarization and produce an action potential more easily than control 
rats with less negative resting potentials when both groups were stimulated by exposure to the 
same current. In other words, an electrical pulse that could depolarize a statin-treated myofiber of 
a large negative resting potential would not be able to induce an action potential in a myofiber at 
the same negative resting potential when not treated prior with statins; to depolarize this non-
statin treated myofiber at this negative value, the same size current would need to be applied to 
the myofiber for a longer duration (Pierno et al. 2006). 
Implications of changes to muscle fiber excitability 
Signs of serious changes to the excitability of the muscle fiber are evident in this study. 
Muscle fibers treated with statins will now contract readily when excited by a current whereas 
before the statin treatment, the same current would elicit an action potential. As a result, this 
change may lead to cramping or repeated contracting of a muscle in patients on statins. These 
results proved the original hypothesis that these lipophilic statins show a greater propensity for 
changing the muscle function evidenced by a decrease in the resting chloride membrane potential 
(gCl), an increase in the sarcolemma depolarization, leading to more action potentials, and 
finally, a more negative voltage threshold for mechanical activation (Pierno et al. 2006). 
Agreeably, the authors also suggest that since no changes were seen morphologically in the 
myofibers of the statin-treated rats besides for the decrease in fiber diameter, changes to the 
blood plasma composition may be a better warning sign of impending myopathy, possibly 
terminating in rhabdomyolysis (Table 6). An interesting finding was the increase in muscle mass 
in the tibialis anterior of the atorvastatin rats, not necessarily indicating hypertrophy, but may 
relate to an increase in protein production due to statins (Pierno et al. 2006). This, however, is 
speculation, but may have some truth. 
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Table 6: Effects of chronic treatment with atorvastatin and fluvastatin on biochemical 
parameters in rat plasma. Source: Pierno et al. 2006 
Plasma 
parameter 
Control Atorvastatin 
10mg·kg
-1
 
Fluvastatin 
5mg·kg
-1
 
Fluvastatin 
20mgkg
-1
 
Myoglobin 
(ng ml
-1
) 
0.14±0.02 0.23±0.01 
*P˂0.02 
0.16±0.02 0.28±0.05 
*P˂0.005 
LDH 
(mU ml
-1
) 
587±76 
 
1255±202 
*P˂0.005 
550±77 
 
915±151 
CK 
(mU ml
-1
) 
1238±217 2118±202 
*P˂0.005 
1468±40 1795±189 
*P˂0.05 
Creatinine 
(mg ml
-1
) 
7±0.3 8±0.5 7±0.8 8±0.6 
Potassium 
(m Eq
-1
) 
5.9±0.3 6.8±0.7 5.5±0.6 5.3±0.6 
Azotemia 
(mg ml
-1
) 
0.48±0.02 0.55±0.04 0.45±0.03 0.62±0.05 
*P˂0.005 
N (samples) 10 6 7 7 
CK, creatine kinase; LDH, lactate dehydrogenase. Each row shows the mean ± SEM of the 
plasma parameters measured from the number of samples as indicated. 
*Significantly different with respect to control (by Bonferroni’s t-test) (Pierno et al. 2006). 
 
 
Conclusions about atorvastatin potency and the possibility of statin accumulation leading to 
toxicity 
Atorvastatin was found more potent than fluvastatin as only 10 mg of atorvastatin 
(compared to 20 mg of fluvastatin) resulted in elevated levels of muscle components in the blood 
plasma (Table 6). Elimination of atorvastatin took longer compared to fluvastatin (Corsini et al. 
1995 cited in Pierno et al. 2006). The researchers also conjectured that results with atorvastatin 
support the view that statins produce myopathy by accumulation, yet accumulation of statins 
leading to toxicity was disproven in the experiment of Sidaway et al. (2009). The question that 
now arises is whether the results that Sidaway and colleagues found after this study in 2006 are 
generalizable findings. A possible reconciliation between the differences in opinion could be that 
Sidaway and colleagues proved that accumulation leading to toxicity did not occur particularly 
with simvastatin, rosuvastatin, and cerivastatin, while Pierno and colleagues tested atorvastatin 
and fluvastatin. While it would be much simpler if the accumulation of the statins could be 
related to their origin (i.e. naturally-derived statins cause accumulation and synthetic statins do 
not or vice versa), this does not resolve the issue as Sidaway and colleagues (2009) used both 
synthetic (rosuvastatin and cerivastatin) and a naturally-derived (simvastatin) statins. Also, the 
differences in opinion on statin accumulation cannot be attributed to lipophilicity as all five of 
the statins tested are thought to be more lipophilic by both sets of researchers.  More research is 
needed to determine whether proof exists in the statin buildup theory from more current research 
studies done within the last few years. Coming back to the potency of atorvastatin in particular, it 
is most curious that even with muscle proteins in the plasma and myoglobinuria discharged from 
the kidneys in the atorvastatin-treated rats, no gross, microscopic damage was seen in the 
myofibers, and no decrease in muscle weight was noted (Pierno et al. 2006). 
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Electromyography findings of statin treatment on skeletal muscle 
Fluvastatin (20 mg/kg/day and 5 mg/kg/day) and atorvastatin (10 mg/kg/day) were tested 
to determine how statins lower the gCl of muscle fibers, leading to myotoxicity. Biweekly, 
electromyography using micro electrodes inserted into the rats’ gastrocnemius muscles was 
performed. Recordings of the electrical activity lasted 3-4 minutes in duration. Abnormalities in 
activity spikes (attributed to myotoxicity) in the muscles of statin-treated rats were determined 
by comparison to controls. Examination of the electromyographs showed that after 7-8 weeks of 
statin treatment, 10% of rats on both the high and low doses of fluvastatin and 20% of those on 
atorvastatin showed additional electrical spikes 500 milliseconds in length, not seen in the 
control rats, occurring after spikes related to muscle movement (Pierno et al. 2009). 
gCl reduction and muscle fiber type 
Results showed between 20-35% decrease in the gCl of the extensor digitorum longus 
muscles of rats on statins compared to the matched controls, yet the soleus muscle did not show 
any significant change in gCl due to statins (Pierno et al. 2009).  
Reversing changes to gCl: 
Chelerythrine as a protein kinase c inhibitor 
Effects on slow and fast twitch muscles after statin administration 
Chelerythrine, a known protein kinase C inhibitor, was added to the extensor digitorum 
longus muscles to see if it stopped the drop in gCl due to subsequent administration of statins. 
The effects of chelerythrine were studied both ex vivo and in vitro. Ex vivo administration of 1 
µmol/L of chelerythrine to the extensor digitorum longus muscles of the control rats showed a 
small increase to the gCl. The results were appropriate as a large increase in the gCl was not 
expected to occur since the extensor digitorum longus muscle is a fast twitch muscle, and the 
ClC-1 channels are already in an open state
9
. Chelerythrine increased the gCl in all three statin 
groups compared to statin administration alone. Of the three statin experimental groups, 
atorvastatin displayed the most significant restoration to the gCl, increasing it by 40% compared 
to control muscles with statin treatment only and raising it to the gCl level of muscles from the 
control rats not on statins (Pierno et al. 2009). 
Decreased body mass and mobility 
Damage to muscle by statins can affect overall health and may limit mobility. Rodents on 
the 20 mg/kg/day dose (higher dose) of fluvastatin began to eat less by weeks 3 and 4 and 
showed a decline in their gross weight. Two out of the ten rats in the experimental group on the 
higher dose of fluvastatin showed difficulty with the righting reflex
10
 and demonstrated evidence 
of paralysis in their lower bodies. The other groups of rats (5 mg/kg/day fluvastatin and 10 
mg/kg/day atorvastatin) fared like the control rats and did not show these movement-related 
issues (Pierno et al. 2006). People taking statins, especially those on high doses should therefore 
be aware of possible disturbances to their weight, gait, and general ease of manipulation of their 
muscles. 
 
 
                                                             
9
 When the researchers tested the effects of atorvastatin 50 µmol/L dose on the soleus muscle in vitro, no reduction 
occurred to the gCl reflecting the already lowered gCl that is found in slow twitch muscles. Further study was then 
focused solely on fast twitch muscles with higher baseline gCls (Pierno et al. 2009).   
10
 The righting reflex tests rodents for the speed at which they are able to return to their natural, ventral position 
(resting on their paws) after being flipped onto their backs. 
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Effects to the excretory system: Alterations in blood plasma leading to changes in urine 
composition 
The excretory system is also affected by statins. Protein that is released into the blood by 
dying muscle is filtered by the kidneys. To determine the effects of the statins (fluvastatin and 
atorvastatin) on both muscle and kidneys, the composition of both the blood plasma and urine 
were studied (Pierno et al. 2006). Damage isolated to muscle tissue was evident when elevated 
levels of the following compounds were seen only in the blood plasma (and not urine): 
myoglobin, lactate dehydrogenase, creatine kinase, potassium, azotemia, or the measure of how 
much nitrogen originating from urea is found in the blood, and/or creatinine. If these compounds 
were found in both the plasma and the urine, kidney filtration was also thought to be impaired. 
The following results were noted (Table 7). 
 
 
Table 7: Blood plasma and urine composition after statin treatment on rats. Source: Pierno et al. 
2006 
 
Statin 20 mg/kg/ day 
Fluvastatin 
5 mg/kg/day 
Fluvastatin 
10 mg/kg/day 
Atorvastatin 
Blood plasma    
Myoglobinemia Increase No change Increase 
Lactate Dehydrogenase No change No change Increase 
Creatine Kinase Increase No change Increase 
Creatinine No change No change No change 
K
+
 No change No change No change 
Azotemia Increase No change No change 
Urine * No change No change 
Myoglobinuria  No change Increase 
Creatinuria  No change No change 
Urinary electrolytes  No change No change 
Na
+
  Decrease Decrease 
K
+
  Decrease No change 
Cl
-
  Decrease No change 
Phosphate  Decrease Decrease 
Proteinuria  Decrease No change 
Changes to the blood (increase, decrease, or no change) are related to the criteria in the control 
rats not on statins. 
*No testing was done on the urine of rats on the 20 mg/kg/day fluvastatin dose. 
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The different treatments with the statins led to varied compositions of the blood plasma 
and urine. Fluvastatin strictly at the higher dose led to increased levels of myoglobinemia. 
Myoglobinemia is the release of the heme-containing pigment called myoglobin into the blood. 
Normally found in skeletal muscle to aid in delivering additional oxygen to these tissues during 
vigorous activity, myoglobin that is released into the blood is filtered by the kidneys. Excessive 
secretion of myoglobin can result in myoglobinuria, urine rich in myoglobin, and ultimately, can 
damage the kidneys and renal failure may result (Shankar et al. 2002). In this experiment, other 
increases in substances and chemicals in the blood due to fluvastatin included plasma creatine 
kinase and azotemia. Atorvastatin led to significant increases in myoglobin, lactate 
dehydrogenase, and creatine kinase in blood plasma (Pierno et al. 2006). 
Motor Neuron Damage: Reports of Amyotrophic Lateral Sclerosis-like symptoms in statin 
users 
A more alarming side effect of statins is the development of lesions on motor neurons. 
Reports from Vigibase, the database for WHO for International Drug Monitoring, picked up on 
over 40 profiles of patients on HMG-CoA reductase inhibitors that contained reports of ‘upper 
motor neuron lesion’ or ‘amyotrophic lateral sclerosis’ symptoms. Amyotrophic Lateral 
Sclerosis (ALS) is a rare, fatal disease in which motor neurons degenerate; the possibility of 
statins causing these effects is very worrisome. If statins do cause damage to motor neurons, 
muscles may become atrophied or weak from lack of proper innervation. Many statins were 
reportedly used that produced ALS-like symptoms by Vigibase including simvastatin, 
atorvastatin, cerivastatin, lovastatin, and rosuvastatin. Other frequently compounded symptoms 
experienced by these patients while taking statins included myalgia, myopathy, falling and 
balance problems, and difficulty with speech and manipulation of the tongue, as well as others 
patients (Edwards et al. 2007). This information is relevant to the caution that must be exercised 
when taking statins. More research is needed to further assess the connection between 
neuromuscular issues and statins. 
Prevention of statin damage to muscle 
PGC-1α inhibits atrogin-1 expression and its implications 
Prevention of lovastatin-induced muscle damage was achieved by the regulation of the 
PGC-1α gene mentioned previously. PGC-1α was determined in other studies (Sandri et al. 2006 
cited in Hanai et al. 2007) to inhibit atrogin-1 expression thereby lessening muscle atrophy. The 
experimenters tested this premise with zebrafish embryos. After injecting the embryos with 
cDNA segments containing the PGC-1α gene, expression of the protein coded for by PGC-1α 
prevented the side effects of lovastatin alone including muscle damage, atrogin-1 expression, and 
muscle cell shrinkage. 
Comparison of mitochondrial activity between embryos given lovastatin with and without 
added PGC-1α cDNA was also examined. Cells with injected PGC-1α showed more active 
mitochondria and increased mitochondria activity than cells without the added gene. Similarly, 
myotubes treated with PGC-1α genes when given lovastatin showed no changes in muscle 
morphology, atrogin-1 expression ceased, and oxidative phosphorylation genes were turned on, 
indicating mitochondria activity (Hanai et al. 2007). 
This experiment suggests the possibilities for PGC-1α to be used to counter the negative 
effects that statins have on muscle tissue. The authors speculate that using a drug to trigger the 
expression of PGC-1α may be a viable option11 (Hanai et al. 2007). Yet, this study is specific to 
                                                             
11
 The authors mention the drug metformin, used to treat type 2 diabetes, as a specific example of a drug that 
increases PGC-1α expression (Hanai et al. 2007) 
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lovastatin and may not allow for generalization to other statins. A second consideration is 
whether this study can be extended beyond myotubes and zebrafish embryos to clinical practice 
on humans. It must also be mentioned, however, that increasing PGC-1α expression may be 
detrimental to other body tissues, and it may reverse the beneficial outcomes that statins have on 
coronary disease, namely increasing HDL cholesterol and lowering LDL cholesterol. More 
research is needed to clarify the side effects of abundant PGC-1α expression on systemic tissue 
and cardiac muscle. Still, the prospect of using a drug that increases PGC-1α expression to 
prevent muscle damage due to statins is very promising. 
Results of knocking out atrogin-1 
Interestingly, the absence of the atrogin-1 gene in zebrafish embryos prevented muscle 
damage due to lovastatin administration or HMG-CoA reductase knock out (Hanai et al. 2007). 
In order to verify that atrogin-1 is the reason for the changes to zebrafish embryos’ skeletal 
muscle seen after lovastatin administration (as opposed to another gene), the atrogin-1 gene was 
knocked out allowing for a survey of the lovastatin-treated muscle. The researchers mimicked 
the procedure used to knock out the HMG-CoA reductase gene (and corresponding mRNA) for 
the atrogin-1 gene
12
. The results demonstrated a significantly lower degree of lovastatin-induced 
damage to the zebrafish’s skeletal muscle with the knock out atrogin-1 gene compared to the 
wild-type that was homozygous for atrogin-1. Further, when the zebrafish lacked both the HMG-
CoA reductase gene and the atrogin-1 gene, distortions to muscle morphology were significantly 
less, leading to the conclusion that eliminating the atrogin-1 gene reverses muscle defects that 
would otherwise be present due to HMG-CoA reductase knock out (Hanai et al. 2007) Targeted 
knockdown of zebrafish HMG-CoA reductase has a muscle phenotype similar to that with 
lovastatin treatment and can be rescued by zebrafish atrogin-1 knockdown). 
Clinical application viability for atrogin-1 
It is questionable as to whether knocking out atrogin-1 can be used clinically to prevent 
statin-induced muscle damage. This process is likely much simpler in less complex and/or less 
developed organisms such as zebrafish embryos compared to humans. Additionally, knocking 
out the atrogin-1 gene may have other repercussions on the body that may far outweigh the 
benefits seen from eliminating the possibility for tissue atrophy. If atrogin-1 targeting was to be 
employed to help statin users, more research and testing would be necessary to determine all of 
the outcomes that result from its expression. 
Statins and cardiac muscle 
Since statins affect skeletal muscle, concern arises as to whether these same effects will 
appear in cardiac muscle tissue. Little of the research presented here indicated any effects, 
positive or negative, to cardiac muscle tissue. However, preliminary findings from the research 
mentioned here seem to indicate that statins do not target cardiac muscle tissue. In the study of 
Mohaupt et al. (2009), ryanodine receptor 3 showed increased expression in skeletal muscle, but 
its analog, ryanodine receptor 1, that is found to a lesser degree in skeletal muscle but principally 
in cardiac muscle, was not significantly expressed as mRNA more than that seen in the control. 
Also, atrogin-1 knock out did not generate defects in cardiac muscle tissue so this method may 
be a possible candidate for negating statins’ effects on skeletal muscle (Serrano et al. 2010 cited 
in Hanai et al. 2007). More examination of the research is needed to determine effects seen to 
cardiac muscle after statin usage. 
                                                             
12
 Zebrafish embryos without the atrogin-1 gene did not show any significant differences in muscle morphology 
compared to atrogin-1expressing muscle cells before administering lovastatin, maintaining the integrity of the trial 
(Hanai et al. 2007). 
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CONCLUSION 
Much research has been done and continues to be performed on statins, which could not 
all be discussed here. Other findings not discussed included statins effects on Ras and Rho 
proteins (Liao and Laufs 2005), applications with cancer patients (Demierre et al. 2005), and 
effects on coagulation and fibrinolysis processes (Krysiak et al. 2003), and much more. Due to 
the lack of a better option to reduce cholesterol levels, statin usage will continue, but it is advised 
that statin usage should be limited to patients with a history of coronary heart disease due to high 
cholesterol levels. It is strongly discouraged for use on patients with heart disease unrelated to 
cholesterol as well as autoimmune and cancer patients if other treatments are viable that have 
been known to improve the condition.  Use of statins by these patients may not help their original 
disease and may cause further complications such as muscle breakdown and possible kidney 
damage. For patients with coronary disease and high cholesterol, it is advised that patients should 
have their blood and urine regularly tested for changes mentioned here, preferably within 1 
month of beginning statin usage and once a month, subsequently. Changes in chemicals, 
specifically creatine kinase, found in the blood does not necessarily mean that a patient should 
cease statin usage on the basis of creatine kinase levels. Although participants with myopathy 
had increased creatine kinase levels, this increase was not limited to the patients taking statins 
(Mohaupt et al. 2009). 
Muscle pain should be reported to the physician immediately, since pain could be a sign 
of damage to muscles (Mohaupt et al. 2009). Also, difficulty with controlling muscle movements 
or speech could be a sign of the rare, but serious, motor neuron damage and should be reported. 
Quality of life and mobility may be reduced with statins if muscle damage is not caught early. In 
addition, statins may not prevent a cardiovascular episode and do not reverse coronary disease 
(Nicholls et al. 2011). Yet, overall statins accomplish their lipid-related tasks well and may even 
produce regression in atheroma size. 
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